More than 150 industry players across the world are presently engaged in evaluating<RootsAnalysis>

Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well.

To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this –

The USD 12 billion (by 2030) financial opportunity within the next generation immune checkpoint modulators market has been analyzed across the following segments:
 Target Disease Indication
 Breast Cancer
 Chronic Lymphocytic Leukemia
 Colorectal Cancer
 Head and Neck Cancer
 Lung Cancer
 Lupus Nephritis
 Melanoma
 Multiple Myeloma
 Primary Sjögren's Syndrome
 Others

 Target Immune Checkpoint
 B7-H3
 CD38
 CD40
 CD47
 Others

 Mechanism of Action
 Inhibitory
 Stimulatory

 Therapeutic Modality
 Monoclonal Antibody
 Small Molecule

 Type of Therapy
 Monotherapy
 Combination Therapy

 Route of Administration
 Intravenous
 Subcutaneous
 Others

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific and the Rest of the World

The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030. report features the following companies, which we identified to be key players in this domain:
 Bristol Myers Squibb
 GlaxoSmithKline
 Incyte
 Novartis
 Trillium Therapeutics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape: Clinical and Preclinical Molecules

5. Market Landscape: Therapies Targeting Cd47

6. Market Landscape: Therapies Targeting 4-1bb

7. Clinic

Leave a Reply

Your email address will not be published. Required fields are marked *